About Genelux Corporation
https://www.genelux.comGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.
CEO
Thomas Zindrick
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
WOODWARD DIVERSIFIED CAPITAL, LLC
Shares:1.84M
Value:$4.81M
VANGUARD GROUP INC
Shares:1.42M
Value:$3.7M
BLEICHROEDER LP
Shares:714K
Value:$1.86M
Summary
Showing Top 3 of 60
About Genelux Corporation
https://www.genelux.comGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $8.19M ▲ | $-7.95M ▼ | 0% | $-0.21 ▼ | $-7.81M ▼ |
| Q2-2025 | $0 | $7.65M ▼ | $-7.46M ▲ | 0% | $-0.2 ▲ | $-7.31M ▲ |
| Q1-2025 | $0 | $7.82M ▼ | $-7.49M ▲ | 0% | $-0.21 ▲ | $-7.68M ▲ |
| Q4-2024 | $0 | $9.75M ▲ | $-8.98M ▼ | 0% | $-0.27 ▼ | $-8.75M ▼ |
| Q3-2024 | $0 | $6.94M | $-6.47M | 0% | $-0.19 | $-6.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $20.91M ▼ | $24.99M ▼ | $6.4M ▼ | $18.59M ▼ |
| Q2-2025 | $27.97M ▼ | $32.25M ▼ | $8.35M ▼ | $23.9M ▼ |
| Q1-2025 | $35.1M ▲ | $38.98M ▲ | $9.14M ▲ | $29.85M ▲ |
| Q4-2024 | $30.89M ▼ | $34.72M ▼ | $8.44M ▲ | $26.27M ▼ |
| Q3-2024 | $34.06M | $40.27M | $7.18M | $33.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.95M ▼ | $-6.58M ▲ | $4.72M ▲ | $0 ▼ | $-1.85M ▲ | $-7.09M ▲ |
| Q2-2025 | $-7.46M ▲ | $-7.06M ▼ | $-2.65M ▼ | $52K ▼ | $-9.66M ▼ | $-7.17M ▼ |
| Q1-2025 | $-7.49M ▲ | $-5.43M ▼ | $3.51M ▼ | $9.57M ▲ | $7.64M ▲ | $-5.46M ▼ |
| Q4-2024 | $-8.98M ▼ | $-4.3M ▲ | $6.67M ▲ | $91K ▲ | $2.46M ▲ | $-4.4M ▲ |
| Q3-2024 | $-6.47M | $-5.75M | $3.99M | $0 | $-1.76M | $-5.78M |
CEO
Thomas Zindrick
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
WOODWARD DIVERSIFIED CAPITAL, LLC
Shares:1.84M
Value:$4.81M
VANGUARD GROUP INC
Shares:1.42M
Value:$3.7M
BLEICHROEDER LP
Shares:714K
Value:$1.86M
Summary
Showing Top 3 of 60